Cargando…

Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis

BACKGROUND: Febuxostat is approved in the United States for the management of hyperuricemia in patients with gout. In November 2017 the FDA released a warning alert on a possible link between febuxostat and cardiovascular disease (CVD) reported in a single clinical trial. OBJECTIVE: To conduct a sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuenca, John A., Balda, Javier, Palacio, Ana, Young, Larry, Pillinger, Michael H., Tamariz, Leonardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378016/ https://www.ncbi.nlm.nih.gov/pubmed/30863448 http://dx.doi.org/10.1155/2019/1076189

Ejemplares similares

Febuxostat and the Black Box Blues
por: Abeles, Aryeh M., et al.
Publicado: (2019)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Effects of Febuxostat on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Al-Abdouh, Ahmad, et al.
Publicado: (2020)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis”
por: Gao, Linggen, et al.
Publicado: (2022)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
por: Bai, Yang, et al.
Publicado: (2023)

Social Determinants of Health Mediate COVID-19 Disparities in South Florida
por: Palacio, Ana, et al.
Publicado: (2020)

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
por: Kim, Sollip, et al.
Publicado: (2017)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis
por: Lin, Tsu-Chen, et al.
Publicado: (2019)

Effect of febuxostat on blood pressure in hyperuricemic patients: A protocol for a systematic review and meta-analysis
por: Yao, Jia, et al.
Publicado: (2020)

Febuxostat methanol solvate
por: Jiang, Qi-Ying, et al.
Publicado: (2011)

Febuxostat ethanol monosolvate
por: Gelbrich, Thomas, et al.
Publicado: (2020)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial
por: Ghang, Byeong-zu, et al.
Publicado: (2022)

Is Prior Zika Virus Infection Associated With Cardiovascular Disease?
por: Vasquez, Diego, et al.
Publicado: (2023)

Patient values and preferences when choosing anticoagulants
por: Palacio, Ana M, et al.
Publicado: (2015)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy
por: Kojima, Sunao, et al.
Publicado: (2019)

Successful adaptation of a research methods course in South America
por: Tamariz, Leonardo, et al.
Publicado: (2017)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

COLORECTAL CANCER SCREENING (CRC) DISPARITIES: A ZIP CODE–LEVEL ANALYSIS
por: Singh, Roshni, et al.
Publicado: (2022)

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
por: MacDonald, Thomas M, et al.
Publicado: (2014)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Prior cardiovascular risk and screening echocardiograms predict hospitalization and severity of coronavirus infection among elderly medicare patients
por: Ghany, Reyan, et al.
Publicado: (2020)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis
por: Liu, Xuzhong, et al.
Publicado: (2018)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
por: Dewi, Christiyanti, et al.
Publicado: (2023)

Erratum to “Prior cardiovascular risk and screening echocardiograms predict hospitalization and severity of coronavirus infection among elderly Medicare patients” [American Journal of Preventive Cardiology 3C (2020) 100090]
por: Ghany, Reyan, et al.
Publicado: (2021)

Efficacy and safety of febuxostat in elderly female patients
por: Mizuno, Tomohiro, et al.
Publicado: (2014)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application
por: Kraev, Krasimir Iliev, et al.
Publicado: (2023)

Effects of Therapies on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
por: Karmacharya, Paras, et al.
Publicado: (2020)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

The Association of Overt and Subclinical Hyperthyroidism with the Risk of Cardiovascular Events and Cardiovascular Mortality: Meta-Analysis and Systematic Review of Cohort Studies
por: Sohn, Seo Young, et al.
Publicado: (2020)

Does Intensive Glucose Control Prevent Cognitive Decline in Diabetes? A Meta-Analysis
por: Peñaherrera-Oviedo, Carlos, et al.
Publicado: (2015)

The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis
por: Murad, M Hassan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bj582urku7lb502fkkv8taviri